Avoiding, Treating & Curing Cancer With the Immune System | Dr. Alex Marson

概览

This episode is a wide-ranging discussion between Andrew Huberman and Dr. Alex Marson about how the immune system works, why cancer emerges, and how modern molecular biology is beginning to turn immune cells into programmable therapies.

The conversation moves from fundamentals, including innate immunity, adaptive immunity, T cells, B cells, thymus selection, antibodies, autoimmunity, inflammation, and antibiotics, into cancer as a genetic and evolutionary disease driven by accumulated mutations.

The central conclusion is that cancer treatment is shifting from broad toxic approaches like chemotherapy toward more precise immune-based strategies, especially checkpoint inhibitors, CAR T cells, CRISPR-engineered T cells, antibody-drug conjugates, and targeted delivery systems such as lipid nanoparticles.

The later sections focus on CRISPR’s mechanism, delivery challenges, ethical limits around germline editing, embryo screening, cell banking, induced pluripotent stem cells, and the next wave of high-throughput cell programming for cancer and autoimmune disease.

分段落总结

[00:00] CAR T Cells and Episode Scope

[事实] Marson explains that CAR T cells are T cells engineered with a lab-designed receptor that can direct them to search for and destroy cancer cells.

[事实] Huberman introduces the episode as a discussion of the immune system, autoimmunity, cancer risk, cancer treatment, and gene-editing technologies.

[事实] The episode frames cancer prevention and treatment as topics that are likely to affect listeners or people close to them.

[02:40] Why Biology Feels Different Now

[事实] Marson says biology is at a materially different moment because DNA sequencing, cellular understanding, CRISPR, lipid nanoparticles, vaccines, and computation are converging.

[事实] He argues that medicine is beginning to give cells instructions in the language of DNA and molecular biology rather than only searching for pills.

[推测] The episode presents modern medicine as moving from observing disease toward directly programming cellular behavior.

[06:00] Innate and Adaptive Immunity

[事实] Marson describes the immune system as a body-wide system evolved mainly to protect against viruses, bacteria, fungi, and other foreign invasions.

[事实] Innate immune cells such as dendritic cells and macrophages act as early alarm systems that detect generic signs of damage or foreign material.

[事实] Adaptive immunity relies heavily on lymphocytes, especially B cells and T cells, which provide more specific immune responses.

[08:30] T Cells, Thymus Selection, and B Cells

[事实] Each T cell generates a largely random receptor that can recognize a specific target, giving the immune system a broad repertoire against threats it has not previously encountered.

[事实] The thymus is where T cells are educated; T cells that recognize self-targets are negatively selected, though this process is not perfect.

[事实] B cells generate antibodies through a similar recombination process and release antibodies into the bloodstream as part of infection protection.

[16:16] Immune Health, Sleep, and Metabolism

[事实] Huberman identifies sleep as something strongly associated with immune support, while Marson says the exact mechanistic basis remains underexplored.

[事实] Marson describes mouse experiments in which a high-fat diet and obesity changed the type of allergic skin inflammation, not merely its intensity.

[事实] In those experiments, drug-like antibodies that helped normal-diet mice did not help obese high-fat-diet mice and may have worsened some responses.

[推测] The discussion suggests that metabolic state can shape immune function in ways that standard laboratory studies may miss.

[19:17] Why Some People Get Sick More Often

[事实] Marson says strong genetic defects in specific immune branches can make people unusually susceptible to certain infections.

[事实] He also says there may be subtler, multi-gene influences and environmental factors that help explain variation in immune robustness.

[事实] Early exposure to foods such as peanuts can help build tolerance in people who are not already allergic, while lack of exposure can contribute to hypersensitivity.

[22:24] Autoimmunity and Immune Balance

[事实] Marson explains that autoimmune diseases arise when normal checks fail and immune cells react against the body’s own tissues.

[事实] He gives rheumatoid arthritis, type 1 diabetes, and multiple sclerosis as examples of autoimmune targeting in joints, insulin-producing pancreatic cells, and myelinated brain cells.

[事实] He says the therapeutic goal is targeted immune control, avoiding broad immunosuppression when possible.

[25:32] Local Versus Systemic Immune Responses

[事实] Marson says systemic illness can occur when immune cells secrete cytokines into the bloodstream.

[事实] Cytokines can produce distributed effects such as fever and a generalized feeling of sickness.

[事实] He notes that some symptoms of infection may come from the immune response going too far before returning under control.

[27:43] Antibiotics and Resistance

[事实] Marson rejects the idea that people need to endure bacterial infections to build a robust immune system.

[事实] He calls antibiotics miraculous when used for susceptible bacterial infections.

[事实] He warns that overuse can contribute to antibiotic resistance and says new antibiotic development is an underfunded area of medicine.

[30:52] Cancer as a Genetic Disease

[事实] Marson says cancer has existed for a very long time and recommends The Emperor of All Maladies for its historical account.

[事实] He defines cancer as a genetic disease in which cells accumulate mutations, lose normal regulation, divide out of control, and may metastasize.

[事实] He describes cancer progression as an evolutionary process in which cells acquire changes that benefit their own growth at the expense of the body.

[34:22] Mutation, DNA Replication, and Cancer Risk

[事实] Marson says DNA replication is imperfect, and mutations can arise as cells divide.

[事实] Most damaging mutations lead cells to die, but mutations that increase growth can be passed to daughter cells and contribute to cancer.

[事实] Smoking increases cancer risk by exposing lung cells to chemicals that cause more DNA damage and mutations.

[37:19] BRCA, UV, and Major Mutagens

[事实] Marson says BRCA mutations account for a minority of all cancers but greatly increase risk for individuals who inherit them.

[事实] He says BRCA testing is recommended when there is a family history of cancer.

[事实] Huberman and Marson discuss excessive UV exposure as a clear DNA damage risk for skin cells.

[40:03] Environmental and Occupational Risks

[事实] Huberman identifies smoking, vaping, laboratory chemicals, radiation, paint thinners, and pesticides as concerns around mutagenic or carcinogenic exposure.

[事实] Marson says exposure to environmental risks is not evenly distributed and that people are often left without clear data about product-level risks.

[推测] The discussion implies that public health guidance is weaker where exposure dose, duration, and real-world mixtures are poorly studied.

[44:01] Radiation, Food, and Relative Risk

[事实] Huberman says he avoids unnecessary dental X-rays but recognizes that X-rays are needed in some cases.

[事实] Marson says he personally avoids airport scanners when possible but does not claim to have data proving the benefit.

[事实] Marson says mutagens change DNA, while carcinogens increase cancer rate; the categories are closely related.

[事实] On charred meat and food dyes, the discussion emphasizes uncertainty, dose, exposure duration, and the difficulty of translating high-dose animal data to everyday human risk.

[48:27] Cancer Risk Is Probabilistic

[事实] Marson says someone can do everything right and still get cancer.

[事实] He warns against attributing a person’s cancer to their personal actions.

[推测] This section pushes back against overly simplistic prevention narratives while still treating known risks such as smoking and excessive UV as meaningful.

[49:37] From Chemotherapy to Immunotherapy

[事实] Marson says chemotherapy remains a major cancer treatment and works by using toxins that are more toxic to cancer cells than healthy cells.

[事实] He says targeted drugs against cancer mutations have helped extend lives, but cancers can evolve resistance.

[事实] He presents cancer immunotherapy as a major shift: using immune cells to distinguish and attack cancer while sparing healthy tissue.

[53:00] Checkpoint Inhibitors

[事实] Marson identifies checkpoint inhibitors such as PD-1 and CTLA-4 drugs as therapies that remove natural brakes on T cells.

[事实] He says melanoma is a major success case for checkpoint inhibition.

[事实] He cites Jimmy Carter’s metastatic melanoma response as an example of tumors shrinking after checkpoint inhibitor treatment.

[54:39] CAR T and the Emily Whitehead Case

[事实] Marson explains that CAR T cells are made by adding DNA encoding an artificial receptor to T cells, then reinfusing those cells into the patient.

[事实] He describes Emily Whitehead as the first pediatric patient treated with CAR T cells for cancer in 2012 after other leukemia treatments failed.

[事实] Her T cells were modified using lentivirus-based delivery, she had a difficult ICU course, and her cancer cells disappeared after treatment was controlled.

[事实] Marson says she was later cured of leukemia and became pre-med at the University of Pennsylvania.

[60:00] CRISPR Meets CAR T

[事实] Marson says 2012 also brought the Charpentier and Doudna Science paper introducing CRISPR as a DNA-rewriting tool.

[事实] His lab focused on combining CRISPR with T-cell biology to make more precise engineered immune therapies.

[事实] He says CRISPR-engineered CAR T cells are now in clinical trials, including efforts to treat solid tumors.

[推测] The episode positions 2012 as a turning point where cancer immunotherapy and programmable gene editing became mutually reinforcing.

[62:04] Solid Tumors and Tumor Evasion

[事实] Marson says solid tumors are challenging because T cells must find the right target and function inside immunosuppressive tumor environments.

[事实] He says CRISPR can be used to add edits that help T cells resist cancer’s immune-evasion strategies.

[推测] Solid tumors are framed as the next major test for whether engineered immune cells can move beyond blood cancers.

[63:03] Aging, CD19, and Target Specificity

[事实] Marson says most cancers increase with age because mutations and damage accumulate over time as cells divide and persist.

[事实] The first CAR T target discussed is CD19, a protein found on many B-cell leukemias and lymphomas.

[事实] CD19 is also present on healthy B cells, but Marson says loss of those B cells is generally tolerable.

[事实] For organs such as pancreas or brain, finding safe targets is harder, so researchers are exploring multi-signal recognition systems similar to two-factor authentication.

[67:12] Ketogenic Diets and Cancer

[事实] Huberman asks whether ketogenic or low-glutamine diets help treat or prevent cancer.

[事实] Marson says he does not know the answer and defers on that topic.

[推测] The exchange leaves diet-based cancer treatment claims as uncertain within this episode.

[68:33] The Origin Story of CRISPR

[事实] Marson traces CRISPR’s importance through DNA sequencing, the human genome project, and the need for tools that could test what DNA sequence changes actually do.

[事实] CRISPR emerged from basic research into repeated DNA sequences in bacteria.

[事实] Those sequences turned out to be part of a bacterial defense system against bacteriophage viruses.

[73:17] How CRISPR Works

[事实] CRISPR-Cas9 combines a protein that cuts DNA with an RNA molecule that guides where the cut happens.

[事实] Because RNA-DNA pairing rules are predictable, researchers can design guide RNAs to target specific DNA sequences.

[事实] Marson says labs can now order guide RNAs, mix them with Cas9 protein, and introduce targeted DNA changes in cells.

[事实] CRISPR can be used to cut out genes, paste in corrective sequences, or add larger genetic programs.

[77:17] Precision, Off-Targets, and New Editors

[事实] Marson says CRISPR precision has improved, but unintended consequences remain possible.

[事实] He describes risks such as off-target cuts, neighboring DNA changes, and rare chromosome damage.

[事实] He discusses base editors, which alter nucleotides without making double-strand breaks, and epigenetic editors, which turn genes on or off without changing DNA letters.

[推测] The field is trying to preserve CRISPR’s programmability while reducing the risk created by DNA cutting.

[82:18] Delivering CRISPR into T Cells

[事实] Marson says delivery is one of the key questions in the field.

[事实] His lab collaborated with Jennifer Doudna and used electroporation to get CRISPR protein-RNA complexes into primary human T cells.

[事实] The lab optimized conditions so CRISPR could enter T cells without killing too many of them.

[事实] Later work expanded from small edits to inserting hundreds or thousands of nucleotides of DNA.

[88:25] Industrial-Scale Engineered T Cells

[事实] Marson says Arsenal Biosciences grew out of this technology and is running clinical trials for solid tumors, including a prostate cancer trial.

[事实] The company can write long DNA programs into patient T cells, including a CAR and additional enhancements.

[事实] The workflow involves collecting patient cells, engineering and expanding them centrally, freezing them, and sending them back for infusion.

[89:21] Preventive and Earlier Cancer Immunotherapy

[事实] Huberman asks whether engineered T cells could someday protect broadly against multiple cancers.

[事实] Marson says the field begins with patients who have exhausted other options because the risk-benefit balance is more acceptable there.

[事实] He hopes therapies can move earlier in diagnosis as safety, precision, and cost improve.

[推测] Preventive whole-body cancer immunotherapy remains aspirational in this conversation, not an available or proven strategy.

[92:31] In-Body Delivery: Viruses, Tropism, and LNPs

[事实] Marson says engineered viruses and virus-like particles can be designed to deliver genetic material to specific cell types based on tropism.

[事实] He explains that lipid nanoparticles, formerly discussed as liposomes, were used to deliver mRNA vaccines.

[事实] LNPs naturally tend to go to the liver, which makes them useful for some liver-based genetic diseases.

[事实] Researchers are engineering LNPs with targeting molecules so they can deliver mRNA or CRISPR to specific cells, including T cells.

[98:47] Making CAR T Cells Without Removing Them

[事实] Marson describes work from the University of Pennsylvania in which LNPs were designed to target T cells in the bloodstream.

[事实] Those LNPs can deliver mRNA that temporarily makes T cells express a CAR.

[事实] This approach could create CAR T-like cells inside the body without removing and engineering cells outside the body.

[100:02] COVID Vaccines, mRNA, and Public Trust

[事实] Huberman identifies mandates, shutdowns, and concern about persistent mRNA expression as major sources of public conflict around COVID vaccines.

[事实] Marson explains mRNA as a temporary intermediate between DNA and protein.

[事实] He says the mRNA vaccine gives cells a temporary instruction to make a small part of the COVID virus.

[事实] Marson says he took the COVID vaccine enthusiastically and says many immunology colleagues did the same.

[103:37] Science, Trauma, and Pandemic Politics

[事实] Marson says society has not talked enough about the trauma and dislocation caused by COVID, deaths, shutdowns, economic disruption, and damaged trust in science.

[事实] He describes Operation Warp Speed as an effort that accelerated vaccine development and regulatory coordination.

[事实] He compares COVID-era disagreement to historical disagreement during the 1793 yellow fever epidemic in Philadelphia.

[110:02] Antibody-Drug Conjugates and T-Cell Engagers

[事实] Marson says antibody-drug conjugates use an antibody for targeting and attach a drug or toxin to kill cancer cells more locally.

[事实] He says radio-ligand therapies attach radioactive isotopes to targeting molecules.

[事实] He frames CAR T cells as another version of targeted delivery: the antibody-like sensor drags a T cell to the cancer cell.

[事实] He describes bispecific T-cell engagers as two-ended antibodies that bring cancer cells and T cells together without genetically modifying the T cells.

[113:52] AI-Designed Protein Targeting

[事实] Marson says Amgen has worked on bispecific T-cell engagers and that he advises Amgen.

[事实] He describes a talk about using AI to design synthetic protein binders for targets on cancer cells.

[推测] AI-designed binders could expand the modular toolkit for directing drugs, cells, or immune responses to specific cancer targets.

[115:51] The CRISPR Babies Case

[事实] Huberman asks about the scientist in China who performed CRISPR edits on embryos.

[事实] Marson says the case involved twins whose father was HIV-positive and an attempted edit to CCR5, a gene whose natural mutations can confer HIV resistance.

[事实] Marson says established methods such as sperm washing could reduce HIV transmission risk, making the need for embryo editing questionable.

[事实] He says the exact results were not peer-reviewed and that there were serious concerns about consent and proceeding despite imperfect edits.

[122:20] Somatic Versus Germline Editing

[事实] Marson says his work focuses on somatic edits in immune cells, not edits that pass to future generations.

[事实] He draws a hard line against introducing genetic edits that will be inherited by the next generation.

[事实] He worries about enhancement edits, popular genetic fads, and loss of human diversity.

[125:00] Embryo Sequencing and Selection

[事实] Huberman asks about deep sequencing embryos during IVF to select against potential disease risks.

[事实] Marson says pre-implantation testing can be understandable when avoiding severe mutations or chromosomal abnormalities.

[事实] He warns that many genetic interpretations become probabilistic and that algorithms may overpromise which embryos are more desirable.

[事实] He recommends Michael Sandel’s The Case Against Perfection as a reflection on what may be lost when people try to engineer toward perfection.

[131:09] Near-Term Clinical Excitement

[事实] Marson says he is hopeful about clinical trials for prostate cancer and multiple myeloma.

[事实] He says CAR T cells that eliminate B cells are being explored for autoimmune diseases such as lupus.

[事实] He also mentions rheumatoid arthritis, childhood diabetes, and multiple sclerosis as autoimmune targets being considered for engineered T-cell therapies.

[事实] He says fibromyalgia remains poorly understood and understudied.

[134:17] High-Throughput CRISPR Maps of T Cells

[事实] Marson says his lab can now introduce thousands to hundreds of thousands of CRISPR modifications into populations of primary human T cells.

[事实] These cells can be tested in tumor-like environments to see which genetic changes produce stronger or more useful immune behaviors.

[事实] His lab uses single-cell RNA sequencing to measure the state of individual cells and connect each state to the CRISPR change inside that cell.

[事实] He says his group released data from 22 million cells with different CRISPR gene inactivations.

[137:59] A Recipe Book for Programmable Immunity

[事实] Marson says these experiments create a functional map of how genes influence cell behavior.

[事实] He expects this map to guide which genes should be added, removed, tuned, or epigenetically edited in future immune therapies.

[推测] The long-term goal is a practical instruction manual for designing immune cells with specific recognition, localization, endurance, and disease-fighting abilities.

[139:03] T-Cell Banking and Induced Pluripotent Stem Cells

[事实] Huberman asks whether people should bank T cells.

[事实] Marson says most people have T cells available and he is not banking his own T cells or advising people generally to do so.

[事实] Huberman then asks about banking fibroblasts or induced pluripotent stem cells based on Yamanaka factors.

[140:12] Yamanaka Factors, iPS Cells, and Programmable Cells

[事实] Marson says induced pluripotent stem cells could potentially provide a limitless supply of T cells.

[事实] He says Shinya Yamanaka has been involved in building iPS cell banks that could be immune-compatible with broad groups of people.

[事实] Marson moved his lab to Gladstone, where both Yamanaka and Jennifer Doudna maintain labs.

[推测] Marson sees the intersection of epigenetic reprogramming and CRISPR gene editing as a major platform for future regenerative and immune therapies.

[143:17] Closing Reflections

[事实] Huberman thanks Marson for explaining the immune system, cancer, molecular biology, gene editing, and autoimmune disease therapies in depth.

[事实] Marson thanks Huberman for providing a forum where scientific details can be discussed at length.

[推测] The episode’s closing reinforces that the discussion is meant as both public education and a snapshot of a fast-moving therapeutic field.

播客点评/总结

[推测] The episode’s main value is that it connects basic immunology to therapeutic engineering without treating the immune system as a black box. Listeners get a coherent path from T-cell receptors and thymus selection to CAR T cells, checkpoint inhibitors, CRISPR edits, and targeted delivery.

[推测] Its strongest sections are the explanations of CAR T, CRISPR-Cas9, CD19 targeting, LNP delivery, and the ethics of germline editing. Marson is careful to distinguish what is already in clinical trials from what remains hopeful or speculative.

[推测] The limitation is that several practical consumer questions, including ketogenic diets for cancer, airport scanner risk, food dyes, and cell banking, remain uncertain or only lightly answered. The episode is strongest as a conceptual and translational science overview, not as a direct medical decision guide.

[推测] This episode is best suited for listeners interested in cancer biology, immunotherapy, gene editing, biotechnology, or the ethics of human enhancement, especially those who want enough mechanistic detail to understand why these therapies are exciting and why they still require caution.